Skip to main content

Table 3 Characteristics of the rural opioid initiative cohort by history of hepatitis C virus treatment, 2018–2020

From: Differences in hepatitis C virus (HCV) testing and treatment by opioid, stimulant, and polysubstance use among people who use drugs in rural U.S. communities

 

Self-reported ever having HCV

HCV Treatment

Received Treatment

Never Received Treatment

N

%

N

%

N

%

TOTAL

944

 

111

12%

833

88%

Age

      

 Median (IQR)

36

(29, 43.5)

42

(34, 53)

35

(29, 42)

Sex

      

 Female

440

47%

48

43%

392

47%

 Male

503

53%

63

57%

440

53%

 Transgender

1

0%

0

0%

1

0%

 Missing

0

0%

0

0%

0

0%

Rural Opioid Initiative Site

      

 Illinois

54

6%

13

12%

41

5%

 Kentucky

135

14%

3

3%

132

16%

 North Carolina

124

13%

19

17%

105

13%

 New England1

199

21%

33

30%

166

20%

 Ohio

127

13%

8

7%

119

14%

 Oregon

45

5%

1

1%

44

5%

 West Virginia

92

10%

6

5%

86

10%

 Wisconsin

168

18%

28

25%

140

17%

Substance use category, past 30 days

 No opioid or stimulant use

26

3%

5

5%

21

3%

 Opioid without stimulant use

94

10%

17

15%

77

9%

 Stimulant without opioid use

86

9%

15

14%

71

9%

 Opioid and stimulant use

738

78%

74

67%

664

80%

  1. 1. Defined as Massachusetts, New Hampshire, and Vermont